Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Trial Profile

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Pembrolizumab (Primary) ; Tabelecleucel (Primary)
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 06 Dec 2018 Status changed from planning to recruiting.
    • 01 Aug 2018 According to an Atara Biotherapeutics media release, US FDA accepted IND to initiate this trial.
    • 27 Feb 2018 According to an Atara Biotherapeutics media release, the company expects to start this trial in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top